CONFIRM antiEstrogen Receptor ER SP1 Rabbit Monoclonal Primary Antibody 250 testsRecalls & reported problems
Ventana Medical Systems, Inc. · Class 2
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 3
- Deaths reported
- 0
- Injuries reported
- 2
- Recalls naming it
- 1
Summary
The FDA's MAUDE database contains 3 adverse event reports that list this exact device (DI 04015630972234), received between Dec 18, 2025 and Feb 17, 2026 — classified as 2 injuries, 1 malfunction.
The most frequently reported specific device problem is “False Negative Result” (3 reports).
1 FDA recall record name this device's identifier.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Reports received per month
Recalls naming this device
- Aug 2, 2018Class ITerminated
Leaking and sticking reagent dispensers for horseradish peroxidase (HRP) dispensers. A false negative IHC result may occur.
Z-3007-2018 · Root cause: Under Investigation by firm · Recall details · FDA record ↗
Most reported problems
Device problems
- False Negative Result3
- Incorrect, Inadequate or Imprecise Result or Readings2
Patient problems
- Insufficient Information2
- No Clinical Signs, Symptoms or Conditions1
Recent adverse event reports
The 3 most recent of 3 reports, in the reporter's own words as published by the FDA.
MalfunctionFeb 17, 2026False Negative Result
THERE WAS AN ALLEGATION OF DISCREPANT NEGATIVE RESULTS WITH THE CONFIRM ANTI-ESTROGEN RECEPTOR (ER) (SP1) RABBIT MONOCLONAL PRIMARY ANTIBODY ASSAY FOR 2 PATIENT SAMPLES TESTED ON A BENCHMARK ULTRA SYSTEM. FOR PATIENT 1, THE TUMOR TISSUE FROM THE BIOPSY WAS NEGATIVE. THE SAME TISSUE BLOCK WAS SENT TO AN EXTERNAL LABORATORY, WHERE THE TUMOR WAS IDENTIFIED AS POSITIVE (50%, POSITIVITY SCORE) ON A BOND SYSTEM. ON (B)(6) 2025, THE SAME TISSUE BLOCK WAS SENT TO ANOTHER LABORATORY, WHERE THE TUMOR WAS EVALUATED AS POSITIVE. ON 17-NOV-2025: FOR PATIENT 2, THE TUMOR WAS EVALUATED AS NEGATIVE. EXTERNAL VERIFICATION ON A BOND SYSTEM USING THE SAME TISSUE BLOCK REVEALED POSITIVE STAINING (40% POSITIVITY SCORE). ON (B)(6) 2025 THE SAME TISSUE BLOCK WAS SENT TO ANOTHER LABORATORY, WHERE THE TUMOR WAS EVALUATED AS POSITIVE.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24365196 ↗InjuryDec 18, 2025False Negative Result; Incorrect, Inadequate or Imprecise Result or Readings; False Negative Result; Incorrect, Inadequate or Imprecise Result or Readings
THERE WAS AN ALLEGATION OF DISCREPANT RESULTS WITH THE CONFIRM ANTI-ESTROGEN RECEPTOR (ER) (SP1) RABBIT MONOCLONAL PRIMARY ANTIBODY ASSAY FOR A PATIENT SAMPLE TESTED ON A BENCHMARK ULTRA STAINER MODULE. THE INITIAL RESULT WAS ER NEGATIVE. THE REPEAT RESULT WAS MODERATE ER POSITIVE. THE PATIENT WAS DIAGNOSED AS TRIPLE NEGATIVE BREAST CANCER (TNBC). WITH THE UPDATED ER-POSITIVE RESULT, IT IS REPORTED THAT THE PATIENT WOULD BE ELIGIBLE FOR HORMONE THERAPY. DESPITE MULTIPLE ATTEMPTS, NO FURTHER INFORMATION RELATED TO THE PATIENT, INCLUDING CURRENT CONDITION, ANY DELETERIOUS EFFECTS, AND DIAGNOSTIC DECISIONS BASED ON THE ASSAY RESULTS, COULD BE OBTAINED.
Patient problems: Insufficient Information
MAUDE report 23838220 ↗InjuryDec 18, 2025False Negative Result; Incorrect, Inadequate or Imprecise Result or Readings; False Negative Result; Incorrect, Inadequate or Imprecise Result or Readings
THERE WAS AN ALLEGATION OF DISCREPANT RESULTS WITH THE CONFIRM ANTI-ESTROGEN RECEPTOR (ER) (SP1) RABBIT MONOCLONAL PRIMARY ANTIBODY ASSAY FOR A PATIENT SAMPLE TESTED ON A BENCHMARK ULTRA STAINER MODULE. THE INITIAL RESULT WAS ER NEGATIVE. THE REPEAT RESULT WAS ER-POSITIVE (1+, 60% POSITIVE TUMOR CELLS). THE PATIENT WAS DIAGNOSED AS TRIPLE NEGATIVE BREAST CANCER (TNBC) AND RECEIVED 7 CYCLES OF CHEMOTHERAPY (NAB-PACLITAXEL) AND PORT SURGERY. WITH THE UPDATED ER-POSITIVE RESULT, IT IS REPORTED THAT THE PATIENT MAY HAVE BENEFITED FROM ENDOCRINE THERAPY ALONE. ADDITIONALLY, IT IS REPORTED THAT THE PATIENT WAS PROGESTERONE RECEPTOR (PR) NEGATIVE AND HER2 LOW 2+. DESPITE MULTIPLE ATTEMPTS, NO FURTHER INFORMATION RELATED TO THE PATIENT, INCLUDING CURRENT CONDITION, ANY DELETERIOUS EFFECTS, AND DIAGNOSTIC DECISIONS BASED ON THE ASSAY RESULTS, COULD BE OBTAINED.
Patient problems: Insufficient Information
MAUDE report 23838213 ↗
Other IMMUNOHISTOCHEMISTRY ANTIBODY ASSAY, ESTROGEN RECEPTOR devices
- BOND™ PA0009Leica Biosystems Newcastle Ltd · Immunohistochemistry Antibody Assay, Estrogen Receptor3 reports
- CONFIRM antiEstrogen Receptor ER SP1 Rabbit Monoclonal Primary Antibody 50 testsVentana Medical Systems, Inc. · IMMUNOHISTOCHEMISTRY ANTIBODY ASSAY, ESTROGEN RECEPTOR2 reports
- BOND™ PA0151Leica Biosystems Newcastle Ltd · Immunohistochemistry Antibody Assay, Estrogen Receptor1 report
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026 · each recall links to the FDA recall notice
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page